SGAM
KYTH

Smith Group Asset Management’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Smith Group Asset Management’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-33,220
Closed -$899K – 461
2013
Q2 		$899K Buy
+33,220
New +$760K 0.04% 186

Other funds holding KYTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Smith Group Asset Management's KYTH Position: Q3 2013 in Review

Smith Group Asset Management sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q3 2013, closing a stake of 33,220 shares — an estimated $899K sold.

Smith Group Asset Management first reported a position in KYTH in Q2 2013 and held it in 1 quarter. The position peaked at $899K in Q2 2013. 83 funds tracked by Wall St. Rank hold KYTH as of Q3 2013.

  • Smith Group Asset Management reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q3 2013 after selling out during the quarter.
  • Smith Group Asset Management sold 33,220 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q3 2013, an estimated $899K.
  • Smith Group Asset Management first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q2 2013 and held it in 1 quarter.
  • Smith Group Asset Management's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $899K in Q2 2013.
  • 83 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q3 2013.

Based on Smith Group Asset Management's 13F filing for Q3 2013, filed 29 Oct 2013.